Company Filing History:
Years Active: 2025
Title: Carsten Henneges: Innovator in Lymphoma Treatment Prediction
Introduction
Carsten Henneges is an accomplished inventor based in South San Francisco, CA. He has made significant contributions to the field of oncology, particularly in improving treatment outcomes for patients with aggressive non-Hodgkin lymphoma. His innovative approach focuses on predicting tolerability to treatments, which can help patients avoid adverse effects from conventional therapies.
Latest Patents
Henneges holds a patent titled "Predicting Tolerability in Aggressive Non-Hodgkin Lymphoma." This patent describes systems and methods that enhance the outcomes for subjects suffering from lymphoma. The technology allows for a more accurate prediction of which patients can tolerate specific treatments. By utilizing a machine-learning model, the method generates a score that indicates the degree of treatment tolerance for individual patients. This predictive capability can significantly improve patient care by identifying those who may benefit from alternative therapies.
Career Highlights
Carsten Henneges is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. His work at Genentech has positioned him at the forefront of research aimed at improving cancer treatment methodologies. With a focus on patient-centric solutions, Henneges continues to contribute to advancements in the medical field.
Collaborations
Throughout his career, Henneges has collaborated with notable colleagues, including Tina Geritz Nielsen and Joseph Nathaniel Paulson. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas, ultimately benefiting the field of oncology.
Conclusion
Carsten Henneges is a pioneering inventor whose work in predicting treatment tolerability for lymphoma patients is making a significant impact in oncology. His contributions are helping to shape the future of cancer treatment, ensuring that patients receive the most effective and safe therapies available.